Wednesday 21st March 2018

Congratulations To Dr Michael Wormstone!

Everyone here at the Trust would like to congratulate Dr Michael Wormstone from the University of East Anglia, on winning an Innovation and Impact award last week.

Find out more from the man himself, as he explains a little more about the award and the project for which the prize was awarded.

“UEA hosted its inaugural Innovation and Impact Awards last week. The awards celebrated staff and students who have shown a strong commitment to innovation and impact. I was a finalist in the Consultancy Project of the Year category and I found out on the evening that I had won.  This award recognises an outstanding consultancy project that can clearly demonstrate a commercial, social, health or cultural impact beyond academia.  The generous support of the Trust underpins our research and this platform is fundamental to allowing engagement with outside organisations and successes such as this recognising the impact of our work. A general overview of the project is provided below.

Improving cataract surgery outcomes

Cataract (a clouding of the lens) affects tens of millions and is treated by surgical removal of the cataract and introduction of an artificial intraocular lens (IOL) into residual lens tissue, which restores visual power. While initially very successful, secondary visual loss often occurs due to a wound-healing response known as posterior capsule opacification (PCO).

Dr Wormstone with the late Prof. George Duncan worked closely with clinical colleagues at Norwich to develop a human lens tissue model that is based on a simulated cataract operation. This is commonly regarded as the premier experimental model to investigate events following cataract surgery. Using this system, factors regulating specific characteristics of PCO have been elucidated and consequently targets for pharmacological treatments identified.

The model has also allowed evaluation of several novel IOL designs and their ability to influence PCO; one design has been in clinical use for more than a decade while another next-generation lens will soon undergo clinical trials. The model continues to be developed and further links with companies to develop their IOL designs have been established. The potential reach of this work could benefit millions of cataract patients.”

 Dr Michael Wormstone FRSM FARVO

Author: admin